skip to Main Content


Biosimilar Rituximab and Adalimumab

CCDRD AG´s medical and pharmacokinetic experts have established and already verified a clinical development strategy for both products.

The strategy has been presented, discussed and verified in scientific advice procedures with the following regulatory agencies:

  • European Medical Agency (EMA)
  • Paul-Ehrlich-Institute (PEI)
Back To Top